Treating allergic and inflammatory conditions
    3.
    发明授权
    Treating allergic and inflammatory conditions 有权
    治疗过敏和炎症状况

    公开(公告)号:US07405223B2

    公开(公告)日:2008-07-29

    申请号:US09760588

    申请日:2001-01-16

    CPC classification number: A61K31/4545 Y10S514/96

    Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.

    Abstract translation: 治疗和/或预防皮肤或上,下呼吸道通路的过敏和炎症状况的方法,例如, 季节性过敏性鼻炎,常年性过敏性鼻炎或慢性感染性荨麻疹,在12岁以上的人中,通过施用一定量的去氯雷他定,例如, 2x2.5mg或5mg /天,足以产生在约2.90ng / mL至约4.54ng / mL范围内的地氯雷他定的几何平均稳态最大血浆浓度,或算术平均稳态最大血浆浓度 的脱氯雷他定在约3.2ng / mL至约5.0ng / mL的范围内。

    Treating allergic and inflammatory conditions
    5.
    发明授权
    Treating allergic and inflammatory conditions 有权
    治疗过敏和炎症状况

    公开(公告)号:US07902208B2

    公开(公告)日:2011-03-08

    申请号:US12155250

    申请日:2008-05-30

    CPC classification number: A61K31/4545 Y10S514/96

    Abstract: A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.

    Abstract translation: 治疗和/或预防皮肤或上,下呼吸道通路的过敏和炎症状况的方法,例如, 季节性过敏性鼻炎,常年性过敏性鼻炎或慢性感染性荨麻疹,在12岁以上的人中,通过施用一定量的去氯雷他定,例如, 2×2.5mg或5mg /天,足以产生在约2.90ng / mL至约4.54ng / mL范围内的地氯雷他定的几何平均稳态最大血浆浓度,或算术平均稳态最大血浆浓度 的脱氯雷他定在约3.2ng / mL至约5.0ng / mL的范围内。

    Continuous low-dose cytokine infusion therapy
    6.
    发明授权
    Continuous low-dose cytokine infusion therapy 有权
    连续低剂量细胞因子输注治疗

    公开(公告)号:US06461605B1

    公开(公告)日:2002-10-08

    申请号:US10104287

    申请日:2002-03-22

    CPC classification number: A61K38/212 A61K47/60 Y10S435/811 Y10S514/894

    Abstract: A method is provided for treating conditions that are susceptible of treatment with a cytokine wherein the undesirable side effects normally associated with cytokine administration are diminished or eliminated. The method comprises continuously administering a low dose of a cytokine to an individual afflicted with a condition susceptible of treatment with the cytokine. In a preferred embodiment of the invention, chronic hepatitis C is treated by administering a low dose amount of interferon.

    Abstract translation: 提供了一种治疗易于用细胞因子治疗的病症的方法,其中通常与细胞因子给药相关的不良副作用减弱或消除。 该方法包括连续施用低剂量的细胞因子给患有易受细胞因子治疗的病症的个体。 在本发明的优选实施方案中,通过施用低剂量的干扰素来治疗慢性丙型肝炎。

Patent Agency Ranking